TickerFacts.

Company research / RGC

Regencell Bioscience Holdings Ltd (RGC)

Build a valuation ↗↓ Download CSV

CIK 0001829667 · Nasdaq · Medicinal Chemicals & Botanical Products

  • Sector Manufacturing

Key ratios (year ended 2026-06-30)

-87.7%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 20-F (annual report) · 2026-10-07

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-30
R&D Expense$1.30M$948.3K$1.07M$1.58M$2.51M$438.3K$386.2K$228.2K
Operating Income-$11.72M-$3.77M-$4.74M-$6.27M-$7.62M-$1.38M-$812.4K-$391.0K
Net Income-$11.70M-$3.58M-$4.30M-$5.87M-$7.45M-$1.35M-$812.4K-$391.0K
EPS (Diluted)-$2.37-$0.72-$0.87-$1.19-$0.58-$0.13-$0.08n/a
Total Assets$14.73M$5.76M$8.44M$12.62M$18.02M$340.1K$514.0Kn/a
Total Liabilities$1.38M$895.3K$219.5K$632.3K$938.0K$4.34M$3.16Mn/a
Shareholders' Equity$13.35M$4.86M$8.22M$12.03M$17.07M-$4.00M-$2.65M-$1.84M
Cash & Equivalentsn/an/an/an/a$6.42M$59.4K$387.0K$243.3K
Operating Cash Flow-$7.70M-$3.11M-$4.00M-$4.96M-$5.27M-$767.3K-$726.6K-$391.0K
Capital Expendituresn/a$152.7K$5.4K$27.4K$780.9Kn/a$117.8Kn/a
Free Cash Flown/a-$3.27M-$4.01M-$4.99M-$6.05Mn/a-$844.4Kn/a
Shares Outstandingn/a494.49M13.01M13.01M13.01M10.00M10.00Mn/a
Weighted Average Diluted Sharesn/a494.49M13.01M13.01M12.81M10.00M10.00Mn/a
EPS (Basic)-$2.37-$0.72-$0.87-$1.19-$0.58$0.13$0.08n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView